{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:31Z","timestamp":1791994591892,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R302-A17469"],"award-info":[{"award-number":["R302-A17469"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R1R204-A12255"],"award-info":[{"award-number":["R1R204-A12255"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18SA0032928"],"award-info":[{"award-number":["NNF18SA0032928"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18OC0052303"],"award-info":[{"award-number":["NNF18OC0052303"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008398","name":"Villum Fonden","doi-asserted-by":"publisher","award":["42066"],"award-info":[{"award-number":["42066"]}],"id":[{"id":"10.13039\/100008398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pink tribute"},{"name":"Einar Willumsens Foundation"},{"name":"Carl and Ellen Hertzs foundation"},{"name":"Phycician Sofus Carl Emil Friis and spouse\u2019s Foundation"},{"name":"Neye Foundation"},{"DOI":"10.13039\/100009512","name":"Agnes and Poul Friis Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009512","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Emil C. Hertz and spouse\u2019s Foundation"},{"DOI":"10.13039\/501100008249","name":"Frimodt-Heineke Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008249","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Olga Doris Friis Foundation"},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite promising preclinical studies, the application of DNA methyltransferase inhibitors in treating patients with solid cancers has thus far produced only modest outcomes. The presence of intratumoral heterogeneity in response to DNA methyltransferase inhibitors could significantly influence clinical efficacy, yet our understanding of the single-cell response to these drugs in solid tumors remains very limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this study, we used cancer\/testis antigen genes as a model for methylation-dependent gene expression to examine the activity of DNA methyltransferase inhibitors and their potential synergistic effect with histone deacetylase inhibitors at the single-cancer cell level. The analysis was performed on breast cancer patient-derived xenograft tumors and cell lines, employing a comprehensive set of techniques, including targeted single-cell mRNA sequencing. Mechanistic insights were further gained through DNA methylation profiling and chromatin structure analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We show that breast cancer tumors and cell cultures exhibit a highly heterogenous response to DNA methyltransferase inhibitors, persisting even under high drug concentrations and efficient DNA methyltransferase depletion. The observed variability in response to DNA methyltransferase inhibitors was independent of cancer-associated aberrations and clonal genetic diversity. Instead, these variations were attributed to stochastic demethylation of regulatory CpG sites and the DNA methylation-independent suppressive function of histone deacetylases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings point to intratumoral heterogeneity as a limiting factor in the use of DNA methyltransferase inhibitors as single agents in treatment of solid cancers and highlight histone deacetylase inhibitors as essential partners to DNA methyltransferase inhibitors in the clinic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03294-x","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T02:29:12Z","timestamp":1737599352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition"],"prefix":"10.1186","volume":"44","author":[{"given":"Mie K.","family":"Jakobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaraby Y.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Staehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Siersbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel G.","family":"Terp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal H. G.","family":"Duijf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd L.","family":"Gammelgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik J.","family":"Ditzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei F.","family":"Kirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Guldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten F.","family":"Gjerstorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"3294_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-019-0174-y","volume":"7","author":"M Guo","year":"2019","unstructured":"Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.","journal-title":"Biomark Res"},{"issue":"1","key":"3294_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5(1):37\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3294_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014;8(3):798\u2013806.","journal-title":"Cell Rep"},{"issue":"5","key":"3294_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccr.2012.03.045","volume":"21","author":"DD De Carvalho","year":"2012","unstructured":"De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21(5):655\u201367.","journal-title":"Cancer Cell"},{"issue":"11","key":"3294_CR5","doi-asserted-by":"publisher","first-page":"e1005840","DOI":"10.1371\/journal.pcbi.1005840","volume":"13","author":"YC Chen","year":"2017","unstructured":"Chen YC, Gotea V, Margolin G, Elnitski L. Significant associations between driver gene mutations and DNA methylation alterations across many cancer types. PLoS Comput Biol. 2017;13(11):e1005840.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"3294_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12920-018-0425-z","volume":"11","author":"A Youn","year":"2018","unstructured":"Youn A, Kim KI, Rabadan R, Tycko B, Shen Y, Wang S. A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes. BMC Med Genomics. 2018;11(1):98.","journal-title":"BMC Med Genomics"},{"issue":"3","key":"3294_CR7","doi-asserted-by":"publisher","first-page":"e17388","DOI":"10.1371\/journal.pone.0017388","volume":"6","author":"S Hagemann","year":"2011","unstructured":"Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE. 2011;6(3):e17388.","journal-title":"PLoS ONE"},{"issue":"1","key":"3294_CR8","first-page":"95","volume":"58","author":"CM Bender","year":"1998","unstructured":"Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2\u2019-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58(1):95\u2013101.","journal-title":"Cancer Res"},{"issue":"1","key":"3294_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1868-7083-6-13","volume":"6","author":"DJ Stewart","year":"2014","unstructured":"Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, et al. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014;6(1):13.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"3294_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1535-7163.MCT-11-0140","volume":"10","author":"P Lund","year":"2011","unstructured":"Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn WC, et al. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther. 2011;10(9):1611\u201323.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3294_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5(3):587\u201398.","journal-title":"Oncotarget"},{"issue":"1","key":"3294_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","volume":"9","author":"N Luo","year":"2018","unstructured":"Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248.","journal-title":"Nat Commun"},{"issue":"2","key":"3294_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.1452","volume":"94","author":"A Serrano","year":"2001","unstructured":"Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2\u2019-deoxycytidine treatment. Int J Cancer. 2001;94(2):243\u201351.","journal-title":"Int J Cancer"},{"issue":"2","key":"3294_CR14","first-page":"361","volume":"169","author":"KB Chiappinelli","year":"2017","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an Interferon Response in Cancer via dsRNA. Including Endogenous Retroviruses Cell. 2017;169(2):361.","journal-title":"Including Endogenous Retroviruses Cell"},{"issue":"5","key":"3294_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating agents Target Colorectal Cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373.","journal-title":"Cell"},{"issue":"7","key":"3294_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1517\/14712598.2010.485188","volume":"10","author":"MF Gjerstorff","year":"2010","unstructured":"Gjerstorff MF, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opin Biol Ther. 2010;10(7):1061\u201375.","journal-title":"Expert Opin Biol Ther"},{"key":"3294_CR17","doi-asserted-by":"publisher","first-page":"215982","DOI":"10.1016\/j.canlet.2022.215982","volume":"552","author":"S Traynor","year":"2023","unstructured":"Traynor S, Terp MG, Nielsen AY, Guldberg P, Jakobsen M, Pedersen PG, et al. DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1. Cancer Lett. 2023;552:215982.","journal-title":"Cancer Lett"},{"key":"3294_CR18","doi-asserted-by":"publisher","first-page":"1247715","DOI":"10.3389\/fimmu.2023.1247715","volume":"14","author":"MF Gjerstorff","year":"2023","unstructured":"Gjerstorff MF. Epigenetic targeting of myeloid-derived suppressor cells: time to move into infectious diseases? Front Immunol. 2023;14:1247715.","journal-title":"Front Immunol"},{"issue":"18","key":"3294_CR19","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.18632\/oncotarget.4694","volume":"6","author":"MF Gjerstorff","year":"2015","unstructured":"Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer\/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6(18):15772\u201387.","journal-title":"Oncotarget"},{"issue":"8","key":"3294_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","volume":"5","author":"AJ Simpson","year":"2005","unstructured":"Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer\/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615\u201325.","journal-title":"Nat Rev Cancer"},{"key":"3294_CR21","doi-asserted-by":"crossref","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8\u2009+\u2009progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023;133(7).","DOI":"10.1172\/JCI165673"},{"issue":"32","key":"3294_CR22","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111(32):11774\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7798","key":"3294_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284\u201390.","journal-title":"Nature"},{"issue":"24","key":"3294_CR24","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1158\/1078-0432.CCR-14-1553","volume":"20","author":"F Fang","year":"2014","unstructured":"Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2014;20(24):6504\u201316.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3294_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/138920371604150429155740","volume":"16","author":"X Fu","year":"2015","unstructured":"Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, et al. Low dose Decitabine Combined with Taxol and Platinum Chemotherapy to treat Refractory\/Recurrent ovarian Cancer: an Open-Label, Single-Arm, phase I\/II study. Curr Protein Pept Sci. 2015;16(4):329\u201336.","journal-title":"Curr Protein Pept Sci"},{"key":"3294_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1476-4598-12-9","volume":"12","author":"Y Li","year":"2013","unstructured":"Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO. Epigenetic reactivation of estrogen receptor-alpha (ERalpha) by genistein enhances hormonal therapy sensitivity in ERalpha-negative breast cancer. Mol Cancer. 2013;12:9.","journal-title":"Mol Cancer"},{"issue":"8","key":"3294_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00432-008-0354-x","volume":"134","author":"J Fan","year":"2008","unstructured":"Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008;134(8):883\u201390.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"27","key":"3294_CR28","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1038\/s41388-019-0799-1","volume":"38","author":"M Wu","year":"2019","unstructured":"Wu M, Sheng L, Cheng M, Zhang H, Jiang Y, Lin S, et al. Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene. 2019;38(27):5425\u201339.","journal-title":"Oncogene"},{"issue":"10","key":"3294_CR29","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/1078-0432.CCR-21-0133","volume":"27","author":"C Wang","year":"2021","unstructured":"Wang C, Liu Y, Dong L, Li X, Yang Q, Brock MV, et al. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in patients with Hodgkin Lymphoma who progressed or relapsed after PD-1 Blockade Monotherapy. Clin Cancer Res. 2021;27(10):2782\u201391.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"3294_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","volume":"37","author":"J Nie","year":"2019","unstructured":"Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to Anti-PD-1 antibody camrelizumab in Relapsed\/Refractory classical Hodgkin Lymphoma. J Clin Oncol. 2019;37(17):1479\u201389.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3294_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","volume":"16","author":"G Yu","year":"2019","unstructured":"Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2019;16(4):401\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"3294_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/annonc\/mdf314","volume":"13","author":"J Goffin","year":"2002","unstructured":"Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol. 2002;13(11):1699\u2013716.","journal-title":"Ann Oncol"},{"key":"3294_CR33","doi-asserted-by":"crossref","unstructured":"Gjerstorff MF, Traynor S, Gammelgaard OL, Johansen S, Pedersen CB, Ditzel HJ et al. PDX models: a Versatile Tool for studying the role of myeloid-derived suppressor cells in breast Cancer. Cancers (Basel). 2022;14(24).","DOI":"10.3390\/cancers14246153"},{"issue":"3","key":"3294_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/15592294.2015.1017198","volume":"10","author":"P Srivastava","year":"2015","unstructured":"Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, et al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237\u201346.","journal-title":"Epigenetics"},{"issue":"11","key":"3294_CR35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.leukres.2014.09.001","volume":"38","author":"P Srivastava","year":"2014","unstructured":"Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014;38(11):1332\u201341.","journal-title":"Leuk Res"},{"issue":"9","key":"3294_CR36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ijc.28865","volume":"135","author":"CS Tellez","year":"2014","unstructured":"Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer. 2014;135(9):2223\u201331.","journal-title":"Int J Cancer"},{"issue":"1","key":"3294_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"12","key":"3294_CR38","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"3294_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41467-018-03217-9","volume":"9","author":"AF Kirkin","year":"2018","unstructured":"Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, et al. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nat Commun. 2018;9(1):785.","journal-title":"Nat Commun"},{"key":"3294_CR40","doi-asserted-by":"crossref","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888\u2013902. e21.","DOI":"10.1016\/j.cell.2019.05.031"},{"issue":"11","key":"3294_CR41","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","volume":"18","author":"LC Li","year":"2002","unstructured":"Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427\u201331.","journal-title":"Bioinformatics"},{"issue":"16","key":"3294_CR42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence Alignment\/Map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics"},{"issue":"9","key":"3294_CR43","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.","journal-title":"Genome Biol"},{"issue":"7381","key":"3294_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature10730","volume":"481","author":"CS Ross-Innes","year":"2012","unstructured":"Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481(7381):389\u201393.","journal-title":"Nature"},{"issue":"4","key":"3294_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576\u201389.","journal-title":"Mol Cell"},{"issue":"1","key":"3294_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.arcmed.2013.10.005","volume":"45","author":"SY Hou","year":"2014","unstructured":"Hou SY, Sang MX, Geng CZ, Liu WH, Lu WH, Xu YY, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res. 2014;45(1):44\u201351.","journal-title":"Arch Med Res"},{"issue":"12","key":"3294_CR47","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1158\/0008-5472.CAN-06-0402","volume":"66","author":"D Sharma","year":"2006","unstructured":"Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006;66(12):6370\u20138.","journal-title":"Cancer Res"},{"issue":"10","key":"3294_CR48","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1101\/gr.257576.119","volume":"30","author":"M Cusack","year":"2020","unstructured":"Cusack M, King HW, Spingardi P, Kessler BM, Klose RJ, Kriaucionis S. Distinct contributions of DNA methylation and histone acetylation to the genomic occupancy of transcription factors. Genome Res. 2020;30(10):1393\u2013406.","journal-title":"Genome Res"},{"key":"3294_CR49","doi-asserted-by":"publisher","first-page":"584024","DOI":"10.3389\/fonc.2020.584024","volume":"10","author":"MK Jakobsen","year":"2020","unstructured":"Jakobsen MK, Traynor S, Staehr M, Duijf PG, Nielsen AY, Terp MG, et al. The Cancer\/Testis Antigen Gene VCX2 is rarely expressed in malignancies but can be epigenetically activated using DNA methyltransferase and histone deacetylase inhibitors. Front Oncol. 2020;10:584024.","journal-title":"Front Oncol"},{"issue":"4","key":"3294_CR50","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","volume":"33","author":"N Blagitko-Dorfs","year":"2019","unstructured":"Blagitko-Dorfs N, Schlosser P, Greve G, Pfeifer D, Meier R, Baude A, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019;33(4):945\u201356.","journal-title":"Leukemia"},{"key":"3294_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-018-0517-9","volume":"10","author":"D Bensaid","year":"2018","unstructured":"Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Gregoire M, et al. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clin Epigenetics. 2018;10:79.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"3294_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1158\/1535-7163.MCT-08-0743","volume":"8","author":"M Rius","year":"2009","unstructured":"Rius M, Stresemann C, Keller D, Brom M, Schirrmacher E, Keppler D, et al. Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009;8(1):225\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3294_CR53","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1248\/bpb.b14-00622","volume":"38","author":"K Ueda","year":"2015","unstructured":"Ueda K, Hosokawa M, Iwakawa S. Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 cells. Biol Pharm Bull. 2015;38(8):1113\u20139.","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"3294_CR54","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s40262-020-00934-7","volume":"59","author":"EJB Derissen","year":"2020","unstructured":"Derissen EJB, Beijnen JH. Intracellular pharmacokinetics of pyrimidine analogues used in Oncology and the correlation with drug action. Clin Pharmacokinet. 2020;59(12):1521\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"3294_CR55","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312.","journal-title":"Blood"},{"issue":"51","key":"3294_CR56","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114(51):E10981\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3294_CR57","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.4049\/jimmunol.1103035","volume":"188","author":"D Yang","year":"2012","unstructured":"Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K. Decitabine and Vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol. 2012;188(9):4441\u20139.","journal-title":"J Immunol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03294-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:20:40Z","timestamp":1737602440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03294-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3294"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03294-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Experimental Animal Committee of The Danish Ministry of Justice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}